Funding Opportunities
What We Fund
At the core of FAST’s mission is a commitment to bring scientific and therapeutic advancements from benchside to bedside. To do so, FAST funds projects at every step in the trajectory of drug development, and we are as dedicated to nurturing promising ideas at their earliest stages as we are to protecting and advancing those that have already shown value.
Application process
At the core of FAST’s mission is a commitment to bring scientific and therapeutic advancements from benchside to bedside. To do so, FAST funds projects at every step in the trajectory of drug development, and we are as dedicated to nurturing promising ideas at their earliest stages as we are to protecting and advancing those that have already shown value.
Looking for a deadline?
There isn’t one. All grant applications are considered on a rolling basis. We move fast so you can too. If you have any questions or want to learn more, please email our science team.
Apply for a Grant
We offer a number of different kinds of grants, so that we can capture the best research from anyone, anywhere, at any time.
The FAST-TRAC (Targeted Research to Advance a Cure) Awards
These are designed to catalyze the creation or enhancement of potential treatments for AS with particular emphasis placed on gene modification, disease modification, and symptom-alleviating therapeutics, along with diverse platforms and tools for high-throughput drug screening. FAST-TRAC Awards are either one- or two-year grants, made in one-year allocations, with a maximum recommended funding of $150,000 per year. For larger budget requests please email science@cureangelman.org for justification.
New Investigator Award
In an effort to attract excellent young researchers to join the field of AS, these awards are granted to promising new scientists looking to start a significant research program focusing on translational research. Applicants are within their first five years of an academic position at an institution/university. New Investigator Awards are either one- or two- year grants, made in one-year allocations, with a maximum recommended funding of $150,000 per year. For larger budget requests please email science@cureangelman.org for justification.
The FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award
This award is available to provide substantial support for comprehensive, translational research platform projects, spanning from pre-clinical research to human candidate drugs, which can then be advanced to the stage where Investigational New Drug (IND) application preparation is enabled. The FAST IMPACT grant welcomes proposals from researchers presenting innovative ideas and exciting proof-of-concept work, with the laser focus of advancing therapeutic opportunities to humans living with Angelman syndrome. Award amounts for a FAST IMPACT Grant can be up to $1,000,000 per year.
FAST Postdoctoral Fellowship
Fellowships provide the necessary resources to support and encourage the development of young scientists who benefit from the mentorship of prominent researchers. Applicants must hold a postdoctoral fellowship position at an institution/university at the time of award submission and throughout the proposed awarded period. The hope is that our fellows will later assume professorial roles in departments around the world, which currently have no representation in Angelman syndrome research to further the mission of FAST. Applicants may request up to $50,000 per year for up to two years for salary, fringe benefits, and consumable costs.
The Innovation Seed Grant
This grant is a funding opportunity designed to support innovative proof-of-concept research to advance the understanding and treatment of Angelman Syndrome. With grant amounts ranging from $10,000 to $50,000, this program encourages groundbreaking research ideas that have the potential to make a significant impact on the field. The grant is open to both individual researchers and collaborative teams, including partnerships between academic institutions and industry entities. Proposals should focus on novel, high-risk, high-reward approaches that could lead to transformative advancements in the treatment, therapeutic target, or biomarker identification for Angelman syndrome. This seed funding is intended to help investigators demonstrate early-stage feasibility and provide FAST scientific proof of principal data needed to apply for potential larger-scale funding opportunities.